PTLA Portola Pharmaceuticals Inc.

-0.61  -2%
Previous Close 26.37
Open 26.57
Price To Book 36.28
Market Cap 1,754,505,460
Shares 68,109,684
Volume 910,153
Short Ratio
Av. Daily Volume 1,069,605

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 updated data due at ASH December 2018 noted ORR 34%; 27% CR and in the PTCL cohort ORR 26%; 7% CR.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
  2. See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
  3. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
  4. What’s Portola’s Growth Strategy for Fiscal 2019?
  5. How Is Portola’s Andexxa Placed in the First Quarter?
  6. Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage
  7. Edited Transcript of PTLA earnings conference call or presentation 8-May-19 12:30pm GMT
  8. 3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results
  9. Portola Pharmaceuticals Inc (PTLA) Q1 2019 Earnings Call Transcript
  10. Why Portola Pharmaceuticals Is Tumbling 14.5% Today
  11. Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Tops Revenue Estimates
  12. Portola Pharmaceuticals: 1Q Earnings Snapshot
  13. Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  14. Portola Pharmaceuticals, Inc. to Host Earnings Call
  15. Did Hedge Funds Drop The Ball On Portola Pharmaceuticals Inc (PTLA)?
  16. Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  17. European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
  18. Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development
  19. Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019